| Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014 AJ Hatswell, G Baio, JA Berlin, A Irs, N Freemantle BMJ open 6 (6), e011666, 2016 | 183 | 2016 |
| Probabilistic sensitivity analysis in cost-effectiveness models: determining model convergence in cohort models AJ Hatswell, A Bullement, A Briggs, M Paulden, MD Stevenson Pharmacoeconomics 36, 1421-1426, 2018 | 112 | 2018 |
| Transparency in decision modelling: what, why, who and how? CJ Sampson, R Arnold, S Bryan, P Clarke, S Ekins, A Hatswell, ... Pharmacoeconomics 37 (11), 1355-1369, 2019 | 66 | 2019 |
| The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK AJ Batty, RN Hansen, LM Bloudek, SF Varon, EJ Hayward, ... Journal of medical economics 16 (7), 877-887, 2013 | 59 | 2013 |
| Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma P Ghione, ML Palomba, AR Patel, S Bobillo, K Deighton, CA Jacobson, ... Blood, The Journal of the American Society of Hematology 140 (8), 851-860, 2022 | 56 | 2022 |
| Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective RB Lipton, A Brennan, S Palmer, AJ Hatswell, JK Porter, S Sapra, G Villa, ... Journal of medical economics 21 (7), 666-675, 2018 | 55 | 2018 |
| Carbetocin versus oxytocin for prevention of post-partum haemorrhage at caesarean section in the United Kingdom: an economic impact analysis HA Van Der Nelson, T Draycott, D Siassakos, CWH Yau, AJ Hatswell European Journal of Obstetrics & Gynecology and Reproductive Biology 210 …, 2017 | 52 | 2017 |
| Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death AJ Hatswell, B Pennington, L Pericleous, D Rowen, M Lebmeier, D Lee Health and quality of life outcomes 12, 1-9, 2014 | 47 | 2014 |
| Real-world evidence use in assessments of cancer drugs by NICE A Bullement, T Podkonjak, MJ Robinson, E Benson, R Selby, AJ Hatswell, ... International Journal of Technology Assessment in Health Care 36 (4), 388-394, 2020 | 46 | 2020 |
| Cost-effectiveness of trifluridine/tipiracil for previously treated metastatic colorectal cancer in England and Wales A Bullement, S Underhill, R Fougeray, AJ Hatswell Clinical colorectal cancer 17 (1), e143-e151, 2018 | 36 | 2018 |
| The Cost Effectiveness of Licensed Oromucosal Midazolam (Buccolam®) for the Treatment of Children Experiencing Acute Epileptic Seizures: An Approach When … D Lee, D Gladwell, AJ Batty, N Brereton, E Tate Pediatric Drugs 15, 151-162, 2013 | 32 | 2013 |
| Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer ER Marriott, G van Hazel, P Gibbs, AJ Hatswell Journal of medical economics 20 (2), 193-199, 2017 | 30 | 2017 |
| The effects of model misspecification in unanchored matching-adjusted indirect comparison: results of a simulation study AJ Hatswell, N Freemantle, G Baio Value in Health 23 (6), 751-759, 2020 | 26 | 2020 |
| Cost effectiveness of avelumab for metastatic Merkel cell carcinoma A Bullement, P Nathan, A Willis, A Amin, C Lilley, C Stapelkamp, ... PharmacoEconomics-open 3, 377-390, 2019 | 25 | 2019 |
| Cost effectiveness of characterised chondrocyte implantation for treatment of cartilage defects of the knee in the UK J Elvidge, A Bullement, AJ Hatswell Pharmacoeconomics 34, 1145-1159, 2016 | 25 | 2016 |
| Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study P Ghione, ML Palomba, H Ghesquieres, S Bobillo, AR Patel, M Nahas, ... Haematologica 108 (3), 822, 2022 | 24 | 2022 |
| Reducing drug wastage in pharmaceuticals dosed by weight or body surface areas by optimising vial sizes AJ Hatswell, JK Porter Applied health economics and health policy 17, 391-397, 2019 | 24 | 2019 |
| Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: an indirect comparison using clinical trial data I Tomazos, AJ Hatswell, S Cataland, P Chen, N Freemantle, Å Lommele, ... Clinical Nephrology 97 (5), 261, 2021 | 23 | 2021 |
| Measuring quality of life in opioid-induced constipation: mapping EQ-5D-3 L and PAC-QOL AJ Hatswell, S Vegter Health economics review 6, 1-7, 2016 | 23 | 2016 |
| A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe DC Lee, D Gladwell, AJ Hatswell, J Porter, N Brereton, E Tate, ... Health economics review 4, 1-15, 2014 | 23 | 2014 |
